4000万美元首付款到账:前沿生物与GSK授权合作协议持续推进中

财中社
Yesterday

  3月18日,前沿生物(688221)发布公告,截至本公告披露日,公司已收到由葛兰素史克(GSK.N)按协议约定支付的4000万美元首付款。

  据悉,2026年2月16日,公司与葛兰素史克签署独家授权许可协议,葛兰素史克将获得两款小核酸(siRNA)管线产品在全球范围内的独家开发、生产及商业化权利。

  2025年前三季度,前沿生物实现收入1.03亿元,归母净利润-1.60亿元。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10